Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
4.430
+0.060 (1.37%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Relmada Therapeutics Employees
Relmada Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,642,670
Market Cap
472.55M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -3 | -15.00% |
| Dec 31, 2023 | 20 | 6 | 42.86% |
| Dec 31, 2022 | 14 | 4 | 40.00% |
| Dec 31, 2021 | 10 | -4 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Puma Biotechnology | 179 |
| Arcturus Therapeutics Holdings | 111 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Rezolute | 68 |
| Prothena Corporation | 67 |
| Atea Pharmaceuticals | 55 |
RLMD News
- 4 days ago - Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Relmada Therapeutics reports Q2 EPS (11c), consensus (20c) - TheFly
- 4 weeks ago - Relmada Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 4 weeks ago - Relmada Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - Relmada Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Relmada Therapeutics appoints Bipin Dalmia as chief business officer - TheFly
- 5 weeks ago - Relmada Therapeutics names Bipin Dalmia chief business officer - TheFly
- 5 weeks ago - Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - GlobeNewsWire